RTX Corporation (RTX) Is Doing Better With Missiles, Says Jim Cramer
Defense contractor RTX Corporation (NYSE:RTX)'s shares have gained 34.7% year-to-date. The stock has gained despite a 9.8% dip in April after the firm announced a massive $850 million impact from tariffs. However, since the dip, the shares are up by 37%, with part of the gains attributed to a successful narrative shift by the firm, according to Cramer. The CNBC TV host believes RTX Corporation (NYSE:RTX)'s approach of initially outlining tariff damage and then reducing it, along with describing strategies to weather the storm, has worked well for the firm. This time, he discussed RTX Corporation (NYSE:RTX), the F-35 stealth fighter aircraft, and missile demand:
'Now you do have this F-35 program, and we can talk about that because we have RTX there. RTX seems to be doing better with that.
Copyright: 36clicks / 123RF Stock Photo
Previously, the CNBC TV host commented on RTX Corporation (NYSE:RTX)'s potential to benefit from European trade negotiations:
'And I think the EU may end up lining up with the President, cause he's the President and the next thing you know we have a deal and we're now providing missiles and RTX is a solid buy. And these big tech stocks will not be taxed. . .'
While we acknowledge the potential of RTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Accenture Acquires The Highlands Consulting Group
NEW YORK & SACRAMENTO, Calif.--(BUSINESS WIRE)--Accenture (NYSE: ACN) has acquired The Highlands Consulting Group, a leading management consulting provider with extensive experience in healthcare, transportation, social services and environmental solutions. This move enhances Accenture's capabilities, particularly in the State of California, where Highlands Consulting has a strong presence and a proven track record of delivering high-impact strategy and consulting services. Ryan Oakes, global Health & Public Services industry practices chair at Accenture, said: 'Highlands Consulting's strong relationships and credentials with state agencies will help us better serve our clients and unlock new opportunities for reinvention that drives growth and innovation. We are confident that this acquisition will deliver greater outcomes for our clients in the State of California and beyond.' Highlands Consulting, founded in 2002 and headquartered in Sacramento, CA, brings a team of professionals with decades of hands-on experience in strategic business and digital planning, organizational and process change, and IT planning and analysis. The combination of Accenture and Highlands Consulting will offer clients an expanded range of services and a deeper pool of talent to address their most pressing challenges. This move underscores Accenture's commitment to growing its presence and service offerings, leveraging Highlands Consulting's established relationships and credentials with key agencies in California. 'This deal is a natural fit for both organizations. We are joining forces to deliver even more value to our clients,' added Mike Cappelluti, President of Highlands Consulting. 'Accenture's scale and resources will enable us to expand our services and capabilities, while our local expertise and long-standing client relationships will provide a solid foundation for Accenture's growth in the State of California.' Highlands Consulting's knowledge of areas like Health & Human Services, transportation and organizational change management will help Accenture further support long-term growth plans for clients. This acquisition aligns with Accenture's broader strategic goals to enhance service offerings in critical sectors and ensure a smooth transition to deliver immediate value to clients. Financial terms of the transaction were not disclosed. Forward-Looking Statements Except for the historical information and discussions contained herein, statements in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'should,' 'likely,' 'anticipates,' 'aspires,' 'expects,' 'intends,' 'plans,' 'projects,' 'believes,' 'estimates,' 'positioned,' 'outlook,' 'goal,' 'target' and similar expressions are used to identify these forward-looking statements. These statements are not guarantees of future performance nor promises that goals or targets will be met, and involve a number of risks, uncertainties and other factors that are difficult to predict and could cause actual results to differ materially from those expressed or implied. These risks include, without limitation, risks that: the transaction might not achieve the anticipated benefits for Accenture; Accenture's results of operations have been, and may in the future be, adversely affected by volatile, negative or uncertain economic and geopolitical conditions and the effects of these conditions on the company's clients' businesses and levels of business activity; Accenture's business depends on generating and maintaining client demand for the company's services and solutions including through the adaptation and expansion of its services and solutions in response to ongoing changes in technology and offerings, and a significant reduction in such demand or an inability to respond to the evolving technological environment could materially affect the company's results of operations; risks and uncertainties related to the development and use of AI could harm the company's business, damage its reputation or give rise to legal or regulatory action; if Accenture is unable to match people and their skills with client demand around the world and attract and retain professionals with strong leadership skills, the company's business, the utilization rate of the company's professionals and the company's results of operations may be materially adversely affected; Accenture faces legal, reputational and financial risks from any failure to protect client and/or company data from security incidents or cyberattacks; the markets in which Accenture operates are highly competitive, and Accenture might not be able to compete effectively; Accenture's ability to attract and retain business and employees may depend on its reputation in the marketplace; if Accenture does not successfully manage and develop its relationships with key ecosystem partners or fails to anticipate and establish new alliances in new technologies, the company's results of operations could be adversely affected; Accenture's profitability could materially suffer due to pricing pressure, if the company is unable to remain competitive, if its cost-management strategies are unsuccessful or if it experiences delivery inefficiencies or fail to satisfy certain agreed-upon targets or specific service levels; changes in Accenture's level of taxes, as well as audits, investigations and tax proceedings, or changes in tax laws or in their interpretation or enforcement, could have a material adverse effect on the company's effective tax rate, results of operations, cash flows and financial condition; Accenture's results of operations could be materially adversely affected by fluctuations in foreign currency exchange rates; Accenture's debt obligations could adversely affect its business and financial condition; changes to accounting standards or in the estimates and assumptions Accenture makes in connection with the preparation of its consolidated financial statements could adversely affect its financial results; as a result of Accenture's geographically diverse operations and strategy to continue to grow in key markets around the world, the company is more susceptible to certain risks; if Accenture is unable to manage the organizational challenges associated with its size, the company might be unable to achieve its business objectives; Accenture might not be successful at acquiring, investing in or integrating businesses, entering into joint ventures or divesting businesses; Accenture's business could be materially adversely affected if the company incurs legal liability; Accenture's work with government clients exposes the company to additional risks inherent in the government contracting environment; Accenture's global operations expose the company to numerous and sometimes conflicting legal and regulatory requirements; if Accenture is unable to protect or enforce its intellectual property rights or if Accenture's services or solutions infringe upon the intellectual property rights of others or the company loses its ability to utilize the intellectual property of others, its business could be adversely affected; Accenture may be subject to criticism and negative publicity related to its incorporation in Ireland; as well as the risks, uncertainties and other factors discussed under the 'Risk Factors' heading in Accenture plc's most recent Annual Report on Form 10-K, as updated in Item 1A, 'Risk Factors' in its Quarterly Report on Form 10-Q for the second quarter of fiscal 2025, and other documents filed with or furnished to the Securities and Exchange Commission. Statements in this news release speak only as of the date they were made, and Accenture undertakes no duty to update any forward-looking statements made in this news release or to conform such statements to actual results or changes in Accenture's expectations. About Accenture Accenture is a leading global professional services company that helps the world's leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 791,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world's leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at
CNBC
22 minutes ago
- CNBC
Meta shares fall on AI restructuring report, while Lilly shrugs off Novo's Ozempic price move
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks aren't moving much Monday as Wall Street waits on retail earnings and a speech from Fed Chair Jay Powell later in the week. Monday's session lacks clear themes, but Meta Platforms stands out as a laggard after a report from The Information said the longtime Club holding is planning the fourth restructuring of its AI team in six months. The story is raising questions in light of Meta's significant investment in recruiting AI talent from other tech companies. Novo price cut : Shares of Club name Eli Lilly are relatively unchanged despite chief rival Novo Nordisk lowering prices for its popular GLP-1 medication. Novo Nordisk announced on Monday that it has cut the price of Ozempic, its popular GLP-1 for Type 2 diabetes, to $499 per month for cash-paying patients that use its NovoCare direct-to-patient program. Novo also announced that it has partnered with GoodRx to offer the same price for Ozempic and the weight-loss drug Wegovy at U.S. pharmacies. While the news may spark concerns that a price war is heating up in a battle for market share, we don't see this specific Ozempic development advancing that narrative. The main reason why is that the cash-pay market for GLP-1s to treat Type 2 diabetes is not as important as it is for their obesity counterparts. It all comes down to insurance coverage, which is much higher for these medications for diabetes than weight loss. Indeed, Lilly does not offer Type 2 diabetes treatment Mounjaro on its LillyDirect platform, while sister drug Zepbound for obesity is on there. Lilly executives were asked about this on the company's August earnings call, and the president of Lilly USA, Ilya Yuffa, had this to say: "With Mounjaro, we have significant coverage. So, over 90% coverage in both commercial as well as [Medicare] Part D. And so, we're not sure if [adding Mounjaro to LillyDirect] necessarily provides additional avenue. With Zepbound, we see significant growth because we do have coverage gaps in commercial. And obviously, we also have coverage gaps without having the ability to cover anti-obesity medications in Part D. So, we see this as an opportunity for us to meet that need. For what it's worth, we still like where Lilly sits in the obesity side of the GLP-1 market. Back in February, Eli Lilly announced that self-pay patients could get Zepbound single dose vials for $499 per month through its LillyDirect platform. That's on par with the price for Wegovy on NovoCare. Since head-to-head studies have found Lilly's Zepbound to be superior to Novo Nordisk's Wegovy on weight loss, patients should continue to prefer Lilly's GLP-1s. We initially downgraded our rating on Eli Lilly after its earnings a few weeks ago, partly due to concerns about a potential price war. However, we reversed course and upgraded the stock back to a buy-equivalent 1 following signs of confidence driven by significant insider buying activity. Nuclear win : Alphabet's Google and the nuclear energy company Kairos Power announced on Monday the deployment of an advanced nuclear plant to the grid. Per the agreement, a reactor operated by Kairos Power will deliver up to 50 megawatts of reliable, 24/7 energy to the Tennessee Valley Authority electric grid that powers Google data centers in Tennessee and Alabama. The electricity will come from Kairos' Hermes 2 plant, which is scheduled to begin operations in 2030. The collaboration underscores how hyperscalers are creating new partnerships with nuclear energy providers to secure, around-the-clock power supply toward the end of the decade. Unlike gas-fired electricity, nuclear power offers tech giants like Alphabet a way to run their data centers on clean energy while advancing their decarbonization goals. While Club name GE Vernova is probably best known for its heavy-duty gas turbines , the power generation company also makes small modular reactors that have gained in popularity, so nuclear developments are important to follow closely. Up next: Palo Alto Networks reports after the closing bell , the first of three Club stocks with earnings this week. Before the opening bell on Tuesday, we'll see earnings from Club name Home Depot , Medtronic , and Viking Holdings . On the data side, we'll see July housing starts and building permits, but we'll take are cue on the housing sector from what Home Depot management says on the earnings call. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Business Insider
29 minutes ago
- Business Insider
Morning Movers: Dayforce surges after potential Thoma Bravo acquisition reports
Stock futures are drifting lower this morning as investors lean into a busy week headlined by Jackson Hole central bank speeches and earnings from major retailers. Small caps are showing outperformance, suggesting rotation after recent megacap strength, particularly in tech. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Geopolitical developments are adding weight as markets are monitoring the potential implications of President Trump's meeting with Ukrainian President Zelensky and European leaders as Washington seeks support for a Ukraine–Russia peace initiative. In pre-market trading, S&P 500 futures fell 0.09%, Nasdaq futures fell 0.14% and Dow futures are flat. Check out this morning's top movers from around Wall Street, compiled by The Fly, and subscribe to the Fly By if you want to know how the markets will open, which stocks will be moving and why. HIGHER – Dayforce (DAY) up 25% after Bloomberg reported Thoma Bravo is in talks to acquire the company Soho House (SHCO) up 16% after entering into definitive agreements pursuant to which an investor group led by MCR and its chairman and CEO Tyler Morse will acquire the outstanding shares not held by certain significant shareholders TeraWulf (WULF) up 11% after reporting Google (GOOGL) will provide an incremental backstop of $1.4B in support of project-related debt financing and will receive warrants to acquire shares of TeraWulf common stock Tonix Pharmaceuticals (TNXP) up 4% after announcing that the FDA approved Tonmya for the treatment of fibromyalgia in adults Novo Nordisk (NVO) up 4% after announcing that the FDA has approved an additional indication for Wegovy based on a supplemental New Drug Application for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis DOWN AFTER EARNINGS – Riskified (RSKD) down 13% LOWER – Strategy (MSTR) and Coinbase (COIN) both down 1% after bitcoin dipped as heightened macro concerns triggered more than $500M in forced selling of long positions. Tesla (TSLA) down 1% after The Times reported British motorists can lease a Tesla EV for about half the cost it was a year ago as the company attempts to boost its faltering sales in the UK
